Developer docs
API playgroundTry for free, no card

Search company profiles

Project Data Sphere

Full company profile

uuid00vh7xl

Namestring
Project Data Sphere
Legal namestring
Project Data Sphere
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Project Data Sphere operates an open-access oncology data sharing platform and a set of closed-access precompetitive research programs, functioning as an independent 501(c)(3) subsidiary of the CEO Roundtable on Cancer (CEORT). The open-access platform houses 252+ de-identified clinical trials and 250,000+ patient records, made available to qualified researchers worldwide at no cost. Closed-access precompetitive projects convene pharmaceutical companies, academic institutions, the FDA, and technology partners around jointly developed AI-driven oncology tools, including autoRECIST (a deep learning system for RECIST 1.1 tumor assessment shown to reduce inter-radiologist variability by approximately 30%), the Total Tumor Burden Index (a volumetric 3D tumor quantification model), and AI-enabled tools within the 2017-launched Immune-Related Adverse Events (irAEs) Initiative. The irAEs Initiative further incorporates the ASPIRE physician community, the STORIES patient community, and has driven the establishment of new ICD-10-CM codes for immunotherapy safety reporting through FDA collaboration.

The business model is that of a 501(c)(3) nonprofit: the platform is offered free of charge to academic and clinical researchers, with no disclosed pricing for data access or tool usage. Revenue, where it exists, derives from member organizations, philanthropic donations, and pharma/industry partnership contributions supporting the mission rather than from direct commercial software sales. The go-to-market is a community-led, precompetitive model — engagement is driven through the parent CEO Roundtable on Cancer's 500+ Gold Standard accredited organizations, 11 FDA-PDS Symposia, FDA Grand Rounds presentations, and thought-leadership channels including the Precision Signals podcast and active social media presence. The primary "customers" in practice are research collaborators and contributing institutions rather than revenue-paying buyers, which distinguishes PDS from commercial oncology analytics vendors.

Short descriptiontext

Project Data Sphere operates an oncology data sharing platform and precompetitive research programs, serving pharmaceutical companies, academic institutions, the FDA, and technology partners with 252+ de-identified clinical trials, AI-driven oncology tools including autoRECIST, and the global irAEs Initiative.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology data sharing, clinical trial platform, precompetitive cancer research, AI tumor assessment, medical imaging analytics
Industry3 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Software Publishers51321
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Oncology Clinical Research Data Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Nonprofit Operations
TypeSubscription Recurring
Description

Project Data Sphere operates as a 501(c)(3) nonprofit subsidiary of the CEO Roundtable on Cancer. Revenue appears to come from organizational membership, donations, and potentially pharmaceutical/industry partnerships supporting the mission. The platform offers open-access data sharing at no cost to researchers.

ceort.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1autoRECIST
Description

Deep learning-powered automation of RECIST 1.1 tumor assessments—reducing ~30% inter-radiologist variability.

ceort.org
+3 more records
Core offering1 text field

Project Data Sphere operates an open-access oncology data-sharing platform hosting 252+ clinical trials and 250,000+ de-identified patient records, paired with AI-driven research tools (e.g., autoRECIST) and named precompetitive research programs that enable pharmaceutical companies, academic researchers, regulators, and technology partners to conduct collaborative cancer research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces inter-radiologist variability in RECIST 1.1 tumor assessments by approximately 30%
+1 more record
Product overview1 text field

Project Data Sphere operates as an independent 501(c)(3) subsidiary of the CEO Roundtable on Cancer, offering two complementary programs: an open-access data sharing platform housing 252+ de-identified clinical trials and 250,000+ patient records, and closed-access precompetitive research projects enabling collaboration between pharma, academia, the FDA, and technology partners on AI-driven oncology tools. The portfolio includes autoRECIST (deep learning-powered tumor assessment automation), the Total Tumor Burden Index (volumetric 3D tumor quantification), the irAEs Initiative (immune-related adverse events research with AI tools), ASPIRE and STORIES communities, and the Precision Signals Podcast—all unified under the mission to accelerate cancer research through data sharing and AI-powered oncology tools.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

FDA collaborates with Project Data Sphere on multiple initiatives including: AI-driven tumor assessment validation (autoRECIST presented at FDA Research Grand Rounds), establishment of ICD-10-CM codes for immune-related adverse events, and hosting of 11 FDA-PDS Symposia. The FDA is a key partner in precompetitive research projects and harmonized clinical trial reporting standards development.

2Pharmaceutical Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharma companies participate in closed-access precompetitive research projects through Project Data Sphere, collaborating on AI-driven oncology tools development. They also contribute clinical trial data to the open-access platform and benefit from shared analysis capabilities.

ceort.org
3Academic Institutions
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic researchers access the open-access data platform and collaborate on precompetitive oncology research alongside pharma, FDA, and technology partners. Academic institutions contribute expertise and research capabilities to joint AI tool development initiatives.

ceort.org
Strategic tierCoreTypeTechnology or Integration
Description

Technology partners collaborate on AI-driven oncology tool development, providing technical infrastructure and AI/ML capabilities. These partnerships enable the development of tools like autoRECIST and TTBI, combining domain expertise in oncology with advanced technology capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vivli operates a clinical research data sharing platform enabling anonymized IPD sharing across sponsors and academic researchers. Like PDS, it focuses on precompetitive data exchange and is mission-aligned, but covers multiple therapeutic areas beyond oncology.

TypeEmerging player
Description

Flatiron aggregates oncology real-world data from EHRs and partners with academia and pharma for research. While primarily commercial and focused on real-world (not trial) data, it shares PDS's oncology focus and emphasis on structured, research-grade datasets.

TypeBroad incumbent
Description

Medidata provides industry-leading EDC, CTMS, and clinical trial analytics used by most major sponsors. As a broad incumbent in clinical trial informatics, it overlaps with PDS in trial data management but operates commercially at much larger scale and lacks a nonprofit, open-access model.

TypeEmerging player
Description

COTA curates oncology real-world data and analytics for providers and life sciences. Like PDS, it is oncology-focused and data-centric, but emphasizes real-world evidence rather than clinical trial data sharing.

5Tempus AI
TypeEmerging player
Description

Tempus builds oncology data and AI platforms combining molecular and clinical data for precision medicine. Comparable to PDS in applying AI to oncology data at scale, but operates commercially with much broader molecular profiling and clinical-decision offerings.

TypeBroad incumbent
Description

Veeva offers life sciences cloud software including CTMS, eTMF, and clinical data solutions used across pharma R&D. Comparable as a life-sciences data/informatics platform, but commercially focused and far broader in scope than PDS's oncology-specific mission.

TypeBroad incumbent
Description

IQVIA is a global leader in clinical research services and life sciences analytics, with deep pharma relationships and proprietary trial/real-world data assets. Comparable in serving pharma oncology research needs, but commercial, end-to-end, and far larger in scale than PDS.

TypeEmerging player
Description

Foundation Medicine provides genomic profiling and partners with pharma on oncology data initiatives. It overlaps with PDS in oncology data collaboration with pharma and FDA, though focused on molecular rather than clinical trial data.

TypeDirect peer
Description

Sage Bionetworks is a nonprofit research organization that builds open-data platforms (e.g., Synapse) and runs precompetitive consortia for biomedical data sharing and analysis. Comparable to PDS in mission, nonprofit structure, and emphasis on collaborative analytics infrastructure.

TypeDirect peer
Description

YODA Project facilitates responsible sharing of clinical trial data with external investigators, mirroring PDS's mission of making de-identified trial data broadly available for independent research. Both operate as neutral data-sharing intermediaries rather than commercial analytics vendors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Project Data Sphere

Oncology Clinical Research Data Platformceoroundtableoncancer.org

Project Data Sphere operates an oncology data sharing platform and precompetitive research programs, serving pharmaceutical companies, academic institutions, the FDA, and technology partners with 252+ de-identified clinical trials, AI-driven oncology tools including autoRECIST, and the global irAEs Initiative.

What Project Data Sphere does

Project Data Sphere operates an open-access oncology data sharing platform and a set of closed-access precompetitive research programs, functioning as an independent 501(c)(3) subsidiary of the CEO Roundtable on Cancer (CEORT). The open-access platform houses 252+ de-identified clinical trials and 250,000+ patient records, made available to qualified researchers worldwide at no cost. Closed-access precompetitive projects convene pharmaceutical companies, academic institutions, the FDA, and technology partners around jointly developed AI-driven oncology tools, including autoRECIST (a deep learning system for RECIST 1.1 tumor assessment shown to reduce inter-radiologist variability by approximately 30%), the Total Tumor Burden Index (a volumetric 3D tumor quantification model), and AI-enabled tools within the 2017-launched Immune-Related Adverse Events (irAEs) Initiative. The irAEs Initiative further incorporates the ASPIRE physician community, the STORIES patient community, and has driven the establishment of new ICD-10-CM codes for immunotherapy safety reporting through FDA collaboration.

The business model is that of a 501(c)(3) nonprofit: the platform is offered free of charge to academic and clinical researchers, with no disclosed pricing for data access or tool usage. Revenue, where it exists, derives from member organizations, philanthropic donations, and pharma/industry partnership contributions supporting the mission rather than from direct commercial software sales. The go-to-market is a community-led, precompetitive model — engagement is driven through the parent CEO Roundtable on Cancer's 500+ Gold Standard accredited organizations, 11 FDA-PDS Symposia, FDA Grand Rounds presentations, and thought-leadership channels including the Precision Signals podcast and active social media presence. The primary "customers" in practice are research collaborators and contributing institutions rather than revenue-paying buyers, which distinguishes PDS from commercial oncology analytics vendors.

Project Data Sphere firmographics

Firmographics
Name
Project Data Sphere
Legal name
Project Data Sphere
Website
https://ceoroundtableoncancer.org
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Project Data Sphere operates an oncology data sharing platform and precompetitive research programs, serving pharmaceutical companies, academic institutions, the FDA, and technology partners with 252+ de-identified clinical trials, AI-driven oncology tools including autoRECIST, and the global irAEs Initiative.
Ownership category
akta.pro rank

Project Data Sphere industry classification

Industry
Product category
Oncology Clinical Research Data Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (51321)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAO
Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Oncology data sharing
  • Clinical trial platform
  • Precompetitive cancer research
  • AI tumor assessment
  • Medical imaging analytics

Where Project Data Sphere is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Project Data Sphere business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Nonprofit Operations: Project Data Sphere operates as a 501(c)(3) nonprofit subsidiary of the CEO Roundtable on Cancer. Revenue appears to come from organizational membership, donations, and potentially pharmaceutical/industry partnerships supporting the mission. The platform offers open-access data sharing at no cost to researchers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Project Data Sphere product offering

Product offering

Core offering

Project Data Sphere operates an open-access oncology data-sharing platform hosting 252+ clinical trials and 250,000+ de-identified patient records, paired with AI-driven research tools (e.g., autoRECIST) and named precompetitive research programs that enable pharmaceutical companies, academic researchers, regulators, and technology partners to conduct collaborative cancer research.

Product overview

Project Data Sphere operates as an independent 501(c)(3) subsidiary of the CEO Roundtable on Cancer, offering two complementary programs: an open-access data sharing platform housing 252+ de-identified clinical trials and 250,000+ patient records, and closed-access precompetitive research projects enabling collaboration between pharma, academia, the FDA, and technology partners on AI-driven oncology tools. The portfolio includes autoRECIST (deep learning-powered tumor assessment automation), the Total Tumor Burden Index (volumetric 3D tumor quantification), the irAEs Initiative (immune-related adverse events research with AI tools), ASPIRE and STORIES communities, and the Precision Signals Podcast—all unified under the mission to accelerate cancer research through data sharing and AI-powered oncology tools.

Differentiator

Problem solved

Functional benefit

Brands

  • autoRECIST: Deep learning-powered automation of RECIST 1.1 tumor assessments—reducing ~30% inter-radiologist variability.
  • Total Tumor Burden Index (TTBI)
  • Immune-Related Adverse Events (irAEs) Initiative
  • Precision Signals Podcast

Quantifiable outcome

  • Reduces inter-radiologist variability in RECIST 1.1 tumor assessments by approximately 30%
  • +1 more outcomes

Companies that use Project Data Sphere

Customer profile

Segments4 records

Ideal customer profiles3 records

Project Data Sphere technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Project Data Sphere partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • FDAcoreStrategic or Co-development PartnerFDA collaborates with Project Data Sphere on multiple initiatives including: AI-driven tumor assessment validation (autoRECIST presented at FDA Research Grand Rounds), establishment of ICD-10-CM codes for immune-related adverse events, and hosting of 11 FDA-PDS Symposia. The FDA is a key partner in precompetitive research projects and harmonized clinical trial reporting standards development.
  • Pharmaceutical CompaniescoreStrategic or Co-development PartnerPharma companies participate in closed-access precompetitive research projects through Project Data Sphere, collaborating on AI-driven oncology tools development. They also contribute clinical trial data to the open-access platform and benefit from shared analysis capabilities.
  • Academic InstitutionscoreStrategic or Co-development PartnerAcademic researchers access the open-access data platform and collaborate on precompetitive oncology research alongside pharma, FDA, and technology partners. Academic institutions contribute expertise and research capabilities to joint AI tool development initiatives.
  • Technology PartnerscoreTechnology or IntegrationTechnology partners collaborate on AI-driven oncology tool development, providing technical infrastructure and AI/ML capabilities. These partnerships enable the development of tools like autoRECIST and TTBI, combining domain expertise in oncology with advanced technology capabilities.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Project Data Sphere competitors and assessment

Company assessment

Direct peers

  • Vivli: Vivli operates a clinical research data sharing platform enabling anonymized IPD sharing across sponsors and academic researchers. Like PDS, it focuses on precompetitive data exchange and is mission-aligned, but covers multiple therapeutic areas beyond oncology.
  • Sage Bionetworks: Sage Bionetworks is a nonprofit research organization that builds open-data platforms (e.g., Synapse) and runs precompetitive consortia for biomedical data sharing and analysis. Comparable to PDS in mission, nonprofit structure, and emphasis on collaborative analytics infrastructure.
  • Yale Open Data Access (YODA) Project: YODA Project facilitates responsible sharing of clinical trial data with external investigators, mirroring PDS's mission of making de-identified trial data broadly available for independent research. Both operate as neutral data-sharing intermediaries rather than commercial analytics vendors.

Emerging players

  • Flatiron Health: Flatiron aggregates oncology real-world data from EHRs and partners with academia and pharma for research. While primarily commercial and focused on real-world (not trial) data, it shares PDS's oncology focus and emphasis on structured, research-grade datasets.
  • COTA Healthcare: COTA curates oncology real-world data and analytics for providers and life sciences. Like PDS, it is oncology-focused and data-centric, but emphasizes real-world evidence rather than clinical trial data sharing.
  • Tempus AI: Tempus builds oncology data and AI platforms combining molecular and clinical data for precision medicine. Comparable to PDS in applying AI to oncology data at scale, but operates commercially with much broader molecular profiling and clinical-decision offerings.
  • Foundation Medicine: Foundation Medicine provides genomic profiling and partners with pharma on oncology data initiatives. It overlaps with PDS in oncology data collaboration with pharma and FDA, though focused on molecular rather than clinical trial data.

Broad incumbents

  • Medidata (Dassault Systèmes): Medidata provides industry-leading EDC, CTMS, and clinical trial analytics used by most major sponsors. As a broad incumbent in clinical trial informatics, it overlaps with PDS in trial data management but operates commercially at much larger scale and lacks a nonprofit, open-access model.
  • Veeva Systems: Veeva offers life sciences cloud software including CTMS, eTMF, and clinical data solutions used across pharma R&D. Comparable as a life-sciences data/informatics platform, but commercially focused and far broader in scope than PDS's oncology-specific mission.
  • IQVIA: IQVIA is a global leader in clinical research services and life sciences analytics, with deep pharma relationships and proprietary trial/real-world data assets. Comparable in serving pharma oncology research needs, but commercial, end-to-end, and far larger in scale than PDS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Project Data Sphere social profiles

Digital presence

Project Data Sphere financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Project Data Sphere leadership team

Management profile

Number of profiles

Profiles2 records

Project Data Sphere funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Project Data Sphere M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Project Data Sphere

What does Project Data Sphere do?

Project Data Sphere operates an open-access oncology data-sharing platform hosting 252+ clinical trials and 250,000+ de-identified patient records, paired with AI-driven research tools (e.g., autoRECIST) and named precompetitive research programs that enable pharmaceutical companies, academic researchers, regulators, and technology partners to conduct collaborative cancer research.

Is Project Data Sphere a public or private company?

Project Data Sphere is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Project Data Sphere founded?

Project Data Sphere was founded in 2001. It employs 1 to 10 people.

Where is Project Data Sphere based?

Project Data Sphere is headquartered in Cary, United States, in the North America region.

How does Project Data Sphere make money?

One revenue line is on record: nonprofit Operations.

Who are Project Data Sphere's main competitors?

Direct peers on record are Vivli, Sage Bionetworks and Yale Open Data Access (YODA) Project. Emerging players are Flatiron Health, COTA Healthcare, Tempus AI and Foundation Medicine. Broad incumbents are Medidata (Dassault Systèmes), Veeva Systems and IQVIA.

Does Project Data Sphere have an API?

No public API is recorded for Project Data Sphere.

What industry is Project Data Sphere in?

Project Data Sphere's product category is Oncology Clinical Research Data Platform. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ProjectdatasphereProject Data SphereProject Data Sphere operates an open-access platform hosting de-identified patient-level oncology data contributed by industry, academia, and research programs to accelerate cancer treatment insights. The platform provides access to over 205 datasets involving more than 260,000 patient lives, supported by SAS analytics tools and partnerships with entities like RTI International and the Agency for Healthcare Research and Quality. Recent additions include data from Brigham and Women's Hospital regarding Vitamin D and Omega-3 trials.DeepscribeAmbient AI for Oncology: How Voice Becomes a Digital Biomarker in Cancer CareIn a podcast discussion, Dr. Sean Khozin, oncologist and CEO of the CEO Roundtable on Cancer and Project Data Sphere, explores with DeepScribe founder Matthew Ko how ambient AI can capture voice signals as digital biomarkers in oncology care, enabling clinicians to detect changes in affect, cadence, and dynamic range that may indicate shifts in patient mood, pain, or neurologic status. Dr. Khozin argues that these voice-derived signals must move from exploratory to validated through FDA regulatory pathways, including software-as-a-medical-device frameworks, to become clinically meaningful biomarkers. The article also highlights Project Data Sphere's pre-competitive collaboration model with regulators and industry to advance digital biomarkers and structured semantic analysis in cancer care.Business Wire BlogQure.ai and Project Data Sphere Combine Big Pharma Insights with Deep AI to Drive Cancer Care ForwardQure.ai and Project Data Sphere announced a partnership to develop autoRECIST, an AI tool for automating tumor response assessments in medical imaging. The collaboration aims to improve efficiency and consistency in evaluating cancer treatments, with input from the FDA and industry stakeholders.PR NewswireNew consensus disease definitions to aid care, accelerate research for cancer patients with side effects from immunotherapiesA team of physicians from 16 institutions, led by neurologists at Massachusetts General Hospital and supported by Project Data Sphere, published consensus disease definitions for neurological toxicities in cancer patients undergoing immune checkpoint inhibitor treatment. These definitions aim to standardize diagnosis and severity criteria, addressing a gap that has hindered patient care and clinical research. The framework will serve as the basis for a multicenter neurologic irAE registry housed at Mass General Hospital.ForbesCollaborative Innovation Is Necessary To Advance In Health CareCollaborative innovation is necessary to advance healthcare, requiring input from diverse stakeholders. Examples include Project Data Sphere and an Intel partnership for Huntington's disease wearables. Barriers like bureaucracy and regulatory practices must be addressed.PR NewswireMerck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data AllianceMerck KGaA, Darmstadt, Germany, announced a strategic collaboration with Project Data Sphere LLC to jointly lead the Global Oncology Big Data Alliance (GOBDA), signed on September 10, 2017, at ESMO 2017 in Madrid, Spain. The alliance aims to expand open-access to de-identified patient data and leverage big data analytics to accelerate cancer research, drug development, and treatment outcomes, building on Project Data Sphere's existing platform containing clinical trial data from nearly 100,000 patients. The initiative is anticipated to run from 2018 to 2021 and will include rare tumor trials, experimental arm data, and real-world patient data, with a joint steering committee monitoring progress including expansion of the database and a planned FDA/Industry immuno-related adverse event safety meeting.